Form 4: Centessa Pharmaceuticals Chief Business Officer Sells Shares Under 10b5-1 Plan

Gregory M. Weinhoff, Chief Business Officer of Centessa Pharmaceuticals plc, sold 11,742 ordinary shares at an average price of $13.6141 under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Gregory M. Weinhoff, the Chief Business Officer of Centessa Pharmaceuticals plc, reported a transaction involving the sale of ordinary shares.
• On April 25, 2025, Weinhoff sold 11,742 ordinary shares at a weighted average price of $13.6141.
• The sales were executed under a Rule 10b5-1 trading plan adopted on May 22, 2024.
• Following the transaction, Weinhoff directly owns 122,279 ordinary shares.
• The price range for the shares sold was between $13.42 and $13.78.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine transaction under a pre-existing trading plan. There's no indication of positive or negative implications for the company's performance.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It's common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information. The market will likely interpret this as a neutral event unless the size of the sale is unusually large or coincides with other negative news.

Comparison to Industry Standards

• Insider sales are a common occurrence in publicly traded companies, and the use of 10b5-1 plans is a standard practice to ensure compliance with insider trading regulations.
• Comparing Weinhoff's transactions to those of other executives in similar biotech companies (e.g., executives at companies like BioNTech, Moderna, or Regeneron) would provide context on the scale and frequency of such sales.
• The adoption of a 10b5-1 trading plan is a common practice among corporate executives to diversify their holdings and avoid any appearance of impropriety related to insider information.

Stakeholder Impact

• The sale of shares by an executive could be perceived neutrally or slightly negatively by shareholders, depending on the context and the size of the transaction.
• However, since the sale was conducted under a pre-arranged 10b5-1 trading plan, it is less likely to cause significant concern.

Key Dates

Keywords

Centessa Pharmaceuticals, CNTA, Gregory Weinhoff, Form 4, Share Sale, Rule 10b5-1, Insider Trading, Chief Business Officer, Ordinary Shares